Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MEDEVICE Capital is a French venture capital fund founded in 2011 by a group of entrepreneurs for entrepreneurs. Based in Paris, the firm focuses on early-stage investments in the health sector, particularly in Medtech and digital health. The fund aims to support innovative companies that address significant medical needs, providing not only financial backing but also strategic and operational assistance.
As the first fund in France specialized exclusively in MedTech and e-Health seed capital, MEDEVICE Capital has established a strong presence in the European startup ecosystem. The firm has a portfolio of 10 companies and emphasizes a hands-on approach to support its investments. The team comprises experienced professionals with extensive backgrounds in healthcare and biomedical fields, which enhances their ability to guide startups toward successful commercialization.
MEDEVICE Capital invests exclusively in innovative startups that tackle pressing medical challenges within the Medtech and digital health sectors. The fund primarily targets early-stage companies in France, with investment tickets ranging from €1 million to €1.5 million at the seed stage, and up to €4 million during Series A funding. MEDEVICE Capital prioritizes companies that can achieve a quick time to market, ideally launching within three years.
The firm emphasizes co-founder level engagement, providing hands-on support across various operational aspects, including R&D, clinical development, industrialization, HR, commercial strategy, and compliance. This operator-led approach allows MEDEVICE Capital to effectively address unmet medical needs and ensure that portfolio companies are well-positioned for success in the competitive healthcare landscape.
MEDEVICE Capital's portfolio includes a diverse range of companies focused on healthcare innovation. Notable active portfolio companies include:
MEDEVICE Capital has also achieved notable exits, including:
Cécile Réal — CEO/Co-founder; a serial entrepreneur and biomedical engineer, she previously served as CEO of Endodiag and Bioprofile.
Nicolas Lascaud — Partner; a tech transfer specialist with a pharmacy doctorate, he has experience as a business manager at Genopole.
Sandra Francisco — Partner; with a background in finance and M&A, she was formerly a product manager at Sanofi and holds a PhD in mathematics from MIT.
Jérôme Descheirder — Partner; a biomedical engineer with experience at GE Healthcare, he specializes in business development.
Gwenaël Servant — Venture Partner; he has a background in life sciences business development and is a co-founder of Epsilon Chimie.
To pitch to MEDEVICE Capital, founders should visit their website and submit their proposals through the designated channel. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. The firm prefers detailed information on the technology and its potential impact on healthcare.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are encouraged, as they can facilitate the review process.
In 2023, MEDEVICE Capital's portfolio company Imactis was acquired by GE HealthCare, marking a significant exit for the firm. This acquisition highlights the firm's ability to identify and support companies with strong growth potential in the healthcare sector.
Additionally, MEDEVICE Capital has seen notable exits in recent years, including Avalun and BePatient, both of which exited in 2021, and Médecin Direct, which exited in 2019. These successful exits demonstrate the firm's effective investment strategy and its focus on high-potential healthcare innovations.
What are MEDEVICE Capital's investment criteria?
MEDEVICE Capital exclusively invests in early-stage companies within the Medtech and digital health sectors. They seek startups that can address significant medical needs and have a clear path to commercialization within three years.
How can I pitch to MEDEVICE Capital?
Founders can submit their pitches through the MEDEVICE Capital website. It is recommended to include a detailed business plan, market analysis, and information on the team and technology.
What makes MEDEVICE Capital different from other venture capital firms?
MEDEVICE Capital emphasizes co-founder level engagement, providing hands-on support across various operational aspects, which differentiates them from many other funds that may take a more passive approach.
What is the typical check size for investments?
MEDEVICE Capital typically invests between €1 million and €1.5 million at the seed stage, with the potential to increase to €4 million during Series A funding rounds.
What geographic areas does MEDEVICE Capital focus on?
The firm primarily invests in early-stage companies located in France, although they have international ambitions.
What kind of post-investment involvement can founders expect?
MEDEVICE Capital provides extensive operational support post-investment, including assistance with R&D, clinical development, and compliance, ensuring that portfolio companies are well-equipped for success.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.